Tigermed-Bdm
Tigermed-Bdm is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Sponsor Geron Corp.
- Start (EU)
- Latest update
- Estimated end
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
Sponsor Neumora Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II)
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants with Major Depressive Disorder
Sponsor Neumora Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1 Dose Finding and Phase 2 Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Evaluate the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) as Monotherapy or in Combination with Lenalidomide as First-Line Therapy for Anthracycline-Ineligible Subjects with Diffuse Large B-Cell Lymphoma
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
First-in-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of GEN1078 in Subjects With Malignant Solid Tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Sponsor Genmab A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Tigermed-Bdm?
The 2026-10-09 snapshot links Tigermed-Bdm to 11 distinct CTIS trials. Recorded services include Statistical analysis, Biometrics (programming and statistics), Biometrics (programming, SDTM & Stats), Biostatistics and Programming, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Tigermed-Bdm?
The most frequently recorded therapeutic areas are Haematological Malignancies, Psychiatry, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Tigermed-Bdm conducted?
The linked trials record locations in 17 countries, including France, Germany, Poland, Denmark, Spain. These are trial locations, not confirmed office locations or countries where Tigermed-Bdm delivered services.
What can this page tell me about Tigermed-Bdm's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Tigermed-Bdm. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Tigermed-Bdm Inc.